文献速递心脑血管急症

老年心肌梗死患者完全或仅罪犯血管PCI

Complete or Culprit-Only PCI in Older Patients with Myocardial Infarction.
PubMed 文献 · N Engl J Med · 2023-08-26
一句话结论≥75岁心肌梗死合并多支病变患者,生理学指导的完全血运重建较仅罪犯血管PCI降低1年死亡、心梗、卒中或任何血运重建复合终点风险(HR 0.73)。

该多中心随机试验纳入1445例≥75岁(中位80岁)心肌梗死合并多支病变、正在接受罪犯病变PCI的患者,随机分为生理学指导的完全血运重建组(720例)和不再进一步血运重建的仅罪犯血管组(725例)。主要终点为1年死亡、心肌梗死、卒中或任何血运重建的复合终点,完全血运重建组113例(15.7%)vs 仅罪犯血管组152例(21.0%)(HR 0.73;95%CI 0.57-0.93;P=0.01)。关键次要终点心血管死亡或心肌梗死为64例(8.9%)vs 98例(13.5%)(HR 0.64;95%CI 0.47-0.88)。安全性终点两组无明显差异(22.5% vs 20.4%;P=0.37)。

要点

  • ≥75岁心肌梗死合并多支病变患者,生理学指导的完全血运重建组1年主要复合终点15.7% vs 仅罪犯血管组21.0%(HR 0.73;95%CI 0.57-0.93;P=0.01)。
  • 关键次要终点心血管死亡或心肌梗死:完全血运重建组8.9% vs 仅罪犯血管组13.5%(HR 0.64;95%CI 0.47-0.88)。
  • 安全性复合终点(对比剂相关急性肾损伤、卒中或出血)两组无明显差异(22.5% vs 20.4%;P=0.37)。
  • 非罪犯病变的功能学显著狭窄通过压力导丝或血管造影识别。
  • 研究纳入中位年龄80岁(四分位距77-84)、女性36.5%、ST段抬高型心肌梗死35.2%的患者。

适用人群与场景

  • ≥75岁、心肌梗死合并多支病变、正在接受罪犯病变经皮冠状动脉介入治疗(PCI)的患者。
  • 中位年龄80岁(四分位距77-84);女性528例(36.5%);因ST段抬高型心肌梗死入院509例(35.2%)。

诊断标准与关键阈值

  • 非罪犯病变的功能学显著狭窄通过压力导丝或血管造影识别。

处置流程与药物剂量

  • 随机分配至生理学指导的完全血运重建组(对非罪犯病变行完全血运重建)或仅罪犯血管组(不再进一步血运重建)。

研究设计与关键结果

  • 多中心随机试验,共1445例患者随机(完全血运重建组720例,仅罪犯血管组725例)。
  • 主要终点(1年死亡、心肌梗死、卒中或任何血运重建复合终点):完全血运重建组113例(15.7%)vs 仅罪犯血管组152例(21.0%)(HR 0.73;95%CI 0.57-0.93;P=0.01)。
  • 关键次要终点(心血管死亡或心肌梗死):完全血运重建组64例(8.9%)vs 仅罪犯血管组98例(13.5%)(HR 0.64;95%CI 0.47-0.88)。
  • 安全性复合终点(对比剂相关急性肾损伤、卒中或出血):完全血运重建组22.5% vs 仅罪犯血管组20.4%(P=0.37)。

证据类型、等级与局限

  • 多中心随机试验。
  • 由Consorzio Futuro in Ricerca等资助;FIRE试验,ClinicalTrials.gov注册号NCT03772743。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 对于≥75岁心肌梗死合并多支病变、正在接受罪犯病变PCI的患者,作者认为生理学指导的完全血运重建较仅罪犯血管PCI可降低1年死亡、心肌梗死、卒中或缺血驱动血运重建的复合终点风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The benefit of complete revascularization in older patients (≥75 years of age) with myocardial infarction and multivessel disease remains unclear.

METHODS: In this multicenter, randomized trial, we assigned older patients with myocardial infarction and multivessel disease who were undergoing percutaneous coronary intervention (PCI) of the culprit lesion to receive either physiology-guided complete revascularization of nonculprit lesions or to receive no further revascularization. Functionally significant nonculprit lesions were identified either by pressure wire or angiography. The primary outcome was a composite of death, myocardial infarction, stroke, or any revascularization at 1 year. The key secondary outcome was a composite of cardiovascular death or myocardial infarction. Safety was assessed as a composite of contrast-associated acute kidney injury, stroke, or bleeding.

RESULTS: A total of 1445 patients underwent randomization (720 to receive complete revascularization and 725 to receive culprit-only revascularization). The median age of the patients was 80 years (interquartile range, 77 to 84); 528 patients (36.5%) were women, and 509 (35.2%) were admitted for ST-segment elevation myocardial infarction. A primary-outcome event occurred in 113 patients (15.7%) in the complete-revascularization group and in 152 patients (21.0%) in the culprit-only group (hazard ratio, 0.73; 95% confidence interval [CI], 0.57 to 0.93; P = 0.01). Cardiovascular death or myocardial infarction occurred in 64 patients (8.9%) in the complete-revascularization group and in 98 patients (13.5%) in the culprit-only group (hazard ratio, 0.64; 95% CI, 0.47 to 0.88). The safety outcome did not appear to differ between the groups (22.5% vs. 20.4%; P = 0.37).

CONCLUSIONS: Among patients who were 75 years of age or older with myocardial infarction and multivessel disease, those who underwent physiology-guided complete revascularization had a lower risk of a composite of death, myocardial infarction, stroke, or ischemia-driven revascularization at 1 year than those who received culprit-lesion-only PCI. (Funded by Consorzio Futuro in Ricerca and others; FIRE ClinicalTrials.gov number, NCT03772743.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Biscaglia S, Guiducci V, Escaned J, et al. Complete or Culprit-Only PCI in Older Patients with Myocardial Infarction. N Engl J Med. 2023. PMID: 37634150. doi:10.1056/NEJMoa2300468

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。